FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283709546> ?p ?o ?g. }

• W4283709546 endingPage "1435" @default.
• W4283709546 startingPage "1435.1" @default.
• W4283709546 abstract "Background Systemic vasculitis (VS) is a severe autoimmune disease requiring active immunosuppressive therapy. The probability of infectious complications in these patients is very high. Immunization with the 23-valent polysaccharide pneumococcal vaccine (PPV-23) is required to reduce the risk of severe respiratory infections in this group of patients. Objectives The aim of the study was to study the tolerability and safety of PPV-23 in patients with SV. Methods At this stage, the study included 13 patients with WS: 10 with vasculitis associated with antineutrophil cytoplasmic antibodies (ANCA) (AAV), (5 with granulomatosis with polyangitis (GPA), 4 with eosinophilic granulomatosis with polyangiitis (EGPA), 2 - with microscopic polyangiitis (MPA)), 1 - with polyarteritis nodosa, 1 - with Takayasu’s arteritis (AT); of which 10 women, 3 men, aged 22 to 76 years. 9 (69%) patients were older than 50 years. Remission of the disease was observed in 1 patient (EGPA), in 3 - low disease activity, in 9 - active vasculitis (all 9 with AAV, BVAS from 4 to 13). All patients received glucocorticoids (GC): 2 - 55-60 mg/day, 9 - 10-20 mg/day, 2-2.5-5 mg/day; 5 -bDMARD: 4 - rituximab (RTM), 1 - TNF inhibitors; 11 - cytostatics (CS): 4 - mycophenolate mofetil (MM), 3 - azathioprine (AZ), 2 - cyclophosphamide (CPh), 2 - methotrexate (MTX). Two patients were on induction therapy (GC 55-60 mg + CPh) with a plan to switch to RTM. Only 1 patient with EGPA received HA as monotherapy. The 23-valent polysaccharide pneumococcal vaccine was administered subcutaneously in 0.5 ml (1 dose). The follow-up period was 1-6 months. During the visits, standard clinical and laboratory tests and the determination of antibodies to S.pneumoniae were carried out. Results Vaccination tolerance was good in all patients. One (7,7%) patient with EGPA (in remission) had a mild local reaction (pain at the injection site) within 1 day. Another 1 (7,7%) patient with severe concomitant pathology (EGPA + multiple sclerosis) had a general reaction in the form of a transient increase in weakness in the lower extremities for up to 5 days (this symptom was a manifestation of polyneuropathy, persisted earlier, and to a greater extent was associated with multiple sclerosis than with EGPA). Vaccinal reactions were completely reversible and did not require additional prescriptions. During the follow-up period, no deterioration in the course of SV was recorded in any case, and no new autoimmune phenomena, both laboratory and clinical, were noted in any of them. 7 (53,8%) patients (all 5 with GPA, 2 with EGPA) had ENT lesions (destructive rhinosinusitis (5), sinusitis (2)) with frequent exacerbations. 1 patient with GPA reported a significant improvement in the condition of the ENT organs (no exacerbations of rhinosinusitis, disappearance of nasal discharge for 5 months). In the remaining 6 patients, the condition also remained stable, no progression of sinusitis was noted during the observation period (1-4 months). No infections of the lower respiratory tract were registered during the observation period. Conclusion 1. All patients had a high risk of infectious complications: combined immunosuppressive therapy (92% of patients), age over 50 years (69% of patients), severe lesion of ENT organs (53,8% of patients). 2. The tolerance of PPV-23 vaccination was good. 3. There was no deterioration in the course of SV. Disclosure of Interests None declared" @default.
• W4283709546 created "2022-06-30" @default.
• W4283709546 creator A5025976331 @default.
• W4283709546 creator A5029441191 @default.
• W4283709546 creator A5037294287 @default.
• W4283709546 creator A5068009044 @default.
• W4283709546 date "2022-05-23" @default.
• W4283709546 modified "2023-09-26" @default.
• W4283709546 title "AB0618 Tolerability and safety of 23-valent polysaccharide pneumococcal vaccine in patients with systemic vasculitis, preliminary results" @default.
• W4283709546 doi "https://doi.org/10.1136/annrheumdis-2022-eular.1487" @default.
• W4283709546 hasPublicationYear "2022" @default.
• W4283709546 type Work @default.
• W4283709546 citedByCount "1" @default.
• W4283709546 countsByYear W42837095462023 @default.
• W4283709546 crossrefType "journal-article" @default.
• W4283709546 hasAuthorship W4283709546A5025976331 @default.
• W4283709546 hasAuthorship W4283709546A5029441191 @default.
• W4283709546 hasAuthorship W4283709546A5037294287 @default.
• W4283709546 hasAuthorship W4283709546A5068009044 @default.
• W4283709546 hasBestOaLocation W42837095461 @default.
• W4283709546 hasConcept C126322002 @default.
• W4283709546 hasConcept C197934379 @default.
• W4283709546 hasConcept C2776015282 @default.
• W4283709546 hasConcept C2776694085 @default.
• W4283709546 hasConcept C2776755627 @default.
• W4283709546 hasConcept C2776760755 @default.
• W4283709546 hasConcept C2777374719 @default.
• W4283709546 hasConcept C2778375690 @default.
• W4283709546 hasConcept C2778910314 @default.
• W4283709546 hasConcept C2779134260 @default.
• W4283709546 hasConcept C2779338263 @default.
• W4283709546 hasConcept C2779664119 @default.
• W4283709546 hasConcept C2780653079 @default.
• W4283709546 hasConcept C2781229154 @default.
• W4283709546 hasConcept C2781253189 @default.
• W4283709546 hasConcept C3020803494 @default.
• W4283709546 hasConcept C523546767 @default.
• W4283709546 hasConcept C54355233 @default.
• W4283709546 hasConcept C71924100 @default.
• W4283709546 hasConcept C86803240 @default.
• W4283709546 hasConcept C90924648 @default.
• W4283709546 hasConceptScore W4283709546C126322002 @default.
• W4283709546 hasConceptScore W4283709546C197934379 @default.
• W4283709546 hasConceptScore W4283709546C2776015282 @default.
• W4283709546 hasConceptScore W4283709546C2776694085 @default.
• W4283709546 hasConceptScore W4283709546C2776755627 @default.
• W4283709546 hasConceptScore W4283709546C2776760755 @default.
• W4283709546 hasConceptScore W4283709546C2777374719 @default.
• W4283709546 hasConceptScore W4283709546C2778375690 @default.
• W4283709546 hasConceptScore W4283709546C2778910314 @default.
• W4283709546 hasConceptScore W4283709546C2779134260 @default.
• W4283709546 hasConceptScore W4283709546C2779338263 @default.
• W4283709546 hasConceptScore W4283709546C2779664119 @default.
• W4283709546 hasConceptScore W4283709546C2780653079 @default.
• W4283709546 hasConceptScore W4283709546C2781229154 @default.
• W4283709546 hasConceptScore W4283709546C2781253189 @default.
• W4283709546 hasConceptScore W4283709546C3020803494 @default.
• W4283709546 hasConceptScore W4283709546C523546767 @default.
• W4283709546 hasConceptScore W4283709546C54355233 @default.
• W4283709546 hasConceptScore W4283709546C71924100 @default.
• W4283709546 hasConceptScore W4283709546C86803240 @default.
• W4283709546 hasConceptScore W4283709546C90924648 @default.
• W4283709546 hasIssue "Suppl 1" @default.
• W4283709546 hasLocation W42837095461 @default.
• W4283709546 hasOpenAccess W4283709546 @default.
• W4283709546 hasPrimaryLocation W42837095461 @default.
• W4283709546 hasRelatedWork W1545201557 @default.
• W4283709546 hasRelatedWork W1985348445 @default.
• W4283709546 hasRelatedWork W1995250273 @default.
• W4283709546 hasRelatedWork W2023796231 @default.
• W4283709546 hasRelatedWork W2077982979 @default.
• W4283709546 hasRelatedWork W2163003110 @default.
• W4283709546 hasRelatedWork W2183655738 @default.
• W4283709546 hasRelatedWork W2266467924 @default.
• W4283709546 hasRelatedWork W2313201560 @default.
• W4283709546 hasRelatedWork W3035913527 @default.
• W4283709546 hasVolume "81" @default.
• W4283709546 isParatext "false" @default.
• W4283709546 isRetracted "false" @default.
• W4283709546 workType "article" @default.